BLTE Profile
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for retinal and metabolic diseases. The company is at the forefront of research aimed at addressing complex conditions such as atrophic age-related macular degeneration (AMD) and autosomal recessive Stargardt disease, which are leading causes of vision loss. Belite Bio's flagship product candidate, LBS-008, is an oral, once-daily treatment designed to manage vitamin A levels in the eye. This therapy aims to reduce the accumulation of toxic vitamin A by-products in ocular tissue, thereby mitigating the progression of these debilitating retinal diseases. LBS-008 is currently undergoing Phase 3 clinical trials, reflecting its advanced development stage and potential impact on vision preservation.
In addition to LBS-008, Belite Bio is advancing LBS-009, another oral therapy targeting liver-related conditions. LBS-009 is designed to inhibit retinol binding protein 4 (RBP4), a protein implicated in various liver diseases, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and type 2 diabetes. This compound is currently in preclinical development, where it is being evaluated for its efficacy and safety in treating these significant metabolic disorders. The development of LBS-009 underscores Belite Bio’s commitment to addressing a broad spectrum of diseases with high unmet medical needs.
Founded in 2016 and headquartered in San Diego, California, Belite Bio, Inc. operates as a subsidiary of Lin Bioscience International Ltd. This affiliation supports Belite Bio’s research and development efforts by leveraging additional resources and expertise in biopharmaceutical innovation. The company's strategic focus is on advancing its pipeline of novel therapeutics through rigorous clinical trials and regulatory processes, with the ultimate goal of improving patient outcomes in critical therapeutic areas.
Belite Bio’s dedication to pioneering drug development in ophthalmology and liver disease reflects its broader mission to tackle complex health challenges with cutting-edge science. By advancing its therapeutic candidates through clinical development, the company aims to bring transformative treatments to market and address the significant needs of patients suffering from these serious and often debilitating conditions.
|
